BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward…
Genmab Unveils Promising Phase 1/2 Data for Rina-S® in Heavily Pretreated Advanced Endometrial Cancer at ASCO 2025 Genmab A/S, a leading biotechnology company specializing in antibody-based therapies for cancer, has…
BeOne Medicines Showcases Early Clinical Success of Two Innovative Breast Cancer Therapies at ASCO 2025 BeOne Medicines Ltd. a global biotechnology company dedicated to developing targeted therapies for cancer, announced…
Viatris Reports Positive Phase 3 Results for MR-142, Advancing a Potential First-in-Class Treatment for Night Vision Impairment in Keratorefractive Patients Viatris Inc. a global healthcare company committed to bridging access…
Jazz Pharmaceuticals Reports Landmark Phase 3 Results for Zepzelca and Tecentriq Combo as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Jazz Pharmaceuticals plc has announced highly promising results…
Traditional Medicine Moves to the Forefront at 78th World Health Assembly, Paving the Way for Global Integration Traditional medicine—long an integral part of diverse cultures and communities across the globe—commanded…
FDA Grants Priority Review to Ascendis Pharma’s NDA for TransCon® CNP in Achondroplasia Treatment Ascendis Pharma A/S a biopharmaceutical company focused on developing innovative therapies for patients with serious rare…
Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from…
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases…
Novartis Highlights Kisqali’s Promise in Reducing Recurrence Risk for Younger Patients with Early Breast Cancer at ASCO 2025 At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis…
AstraZeneca’s Camizestrant Shows Landmark Efficacy in Advanced HR-Positive Breast Cancer with ESR1 Mutations in Phase III SERENA-6 Trial In a pivotal breakthrough for hormone receptor (HR)-positive, HER2-negative advanced breast cancer,…
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing…